The abstract is read at the publisher; the summary is JClub's.
CD49f Hi marks a stem-like subset of human memory CD8+ and CD4+ T cells, linked to higher LEF1/TCF1/CCR7 and improved therapeutic performance.
- Why it matters: Adoptive T cell therapies vary because starting populations are heterogeneous, limiting consistent durability, expansion, and differentiation needed for reliable clinical outcomes.
- What they did: The study profiled CD49f Hi versus CD49f Lo memory T cells by transcriptional and phenotypic markers, then tested clinical CMV-specific T cell products in solid-organ transplant recipients and CAR T cells in a preclinical lymphoma model.
- The result: CD49f Hi–enriched autologous virus-specific T cell therapies in transplant recipients showed superior immune reconstitution and greater in vivo expansion of CMV-specific T cells, and CD19 CAR T cells from CD49f Hi memory T cells had improved persistence and survival in lymphoma.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.